Intriguingly, we artificially induced “synthetic lethality” by disrupting this signaling axis through a CK2 inhibitor (silmitasertib) or SPOP inhibitor (SPOP-IN-6b), finally enhancing the therapeutic efficacy of PARP inhibitors in patients with PCa. This evidence concerns the gene SPOP and posterior cortical atrophy.